HOME Top Market Reports Nuclear Medicine/Radiopharmaceuticals Market by Type (Diagnostic (SPECT - Technetium, PET - F-18), Therapeutic (Beta Emitters - I-131, Alpha Emitters, Brachytherapy - Y-90) & by Application (Oncology, Thyroid, Cardiology) - Global Forecasts to 2021

Nuclear Medicine/Radiopharmaceuticals Market by Type (Diagnostic (SPECT - Technetium, PET - F-18), Therapeutic (Beta Emitters - I-131, Alpha Emitters, Brachytherapy - Y-90) & by Application (Oncology, Thyroid, Cardiology) - Global Forecasts to 2021

By: marketsandmarkets.com
Publishing Date: October 2016
Report Code: PH 3590

Discount on Reports  

  Speak to Analyst Enquiry Before Buying Webinar
purchase report
download pdf  request for customisation


The nuclear medicine/radiopharmaceuticals market is projected to reach USD 7.27 Billion by 2021 from USD 4.67 Billion in 2016, growing at a CAGR of 9.3% during the forecast period. Growth of the overall market can be attributed to factors such as the increasing number of chronic diseases like cancer, development of alpha radiotherapy, and investments through public-private partnerships.

The global market is segmented on the basis of type, application, procedural volume, and region. On the basis of type, the diagnostic radiopharmaceuticals segment is expected to command the largest share of the global market; it is also expected to grow at the highest CAGR during the forecast period. The large market share and high growth rate of this segment can be attributed to the production of MO-99 in the U.S., approval of radiopharmaceuticals by the FDA, new irradiation facility in Germany, installation of PET scanners in India, investments by the government in the Rest of Asia-Pacific, and initiatives of IAEA (International Atomic Energy Agency).

On the basis of application, the SPECT applications segment is estimated to account for the largest share of the global nuclear medicine market. However, the PET segment is projected to register the highest growth rate in the forecast period. A number of factors, such as advances in PET imaging techniques and equipment and the introduction of new PET radiotracers, are making it the desired choice for diagnosis.

In the coming years, the market is expected to witness the highest growth in the Asia-Pacific region. This regional segment is also expected to account for the largest share of the global market. This can be attributed to the installations of PET scanners and increased production of radiopharmaceuticals for therapeutic purposes in India, aging population, high healthcare expenditure in Japan and China, and initiatives by the Australian government.

Some of the major players in the global nuclear medicine market include Cardinal Health Inc. (U.S.), Mallinckrodt plc (Ireland), GE Healthcare (U.K.), Lantheus Medical Imaging, Inc. (U.S.), Bayer AG (Germany), Bracco Imaging S.p.A (Italy), Eczacibasi-Monrol Nuclear Products (Turkey), Nordion, Inc. (Canada), Advanced Accelerator Applications S.A. (France), and IBA Molecular Imaging (Belgium).

Stakeholders of the Nuclear Medicine Market 

  • Radiopharmaceutical/Radioisotope Manufacturers and Distributors
  • Healthcare Institutions (Hospitals, Medical Schools, and Outpatient Clinics)
  • Research and Consulting Firms
  • Research Institutes
  • Venture Capitalists
  • Contract Manufacturing Organizations (CMOs)
  • Contract Research Organizations (CROs)

To know about the assumptions considered for the study, download the pdf brochure

Scope of the Report:

This research report categorizes the global nuclear medicine market into the following segments:

Nuclear Medicine Market, by Type

  • Diagnostic Nuclear Medicine/Radiopharmaceuticals
    • SPECT Radiopharmaceuticals
      • Tc-99
      • Tl-201
      • Ga-67
      • I-123
      • Others
    • PET Radiopharmaceuticals
      • F-18
      • Ru-82
      • Others
  • Therapeutic Nuclear Medicine/Radiopharmaceuticals
    • Beta Emitters
      • I-131
      • Sm-153
      • Rh-186
      • Y-90
      • Lu-177
      • Others
    • Alpha Emitters
      • Ra-223
    • Brachytherapy
      • I-125
      • Ir-192
      • Pa-103
      • Cs-131
      • Others

Nuclear Medicine Market, by Procedural Volumes

  • Diagnostic Procedures
    • SPECT Radiopharmaceuticals
    • PET Radiopharmaceuticals
  • Therapeutic Procedures
    • Beta Emitters
    • Alpha Emitters
    • Brachytherapy

Nuclear Medicine Market, by Application

  • Diagnostic Applications
    • SPECT
      • Cardiology
      • Lymphoma
      • Thyroid
      • Neurology
      • Others
    • PET
      • Oncology
      • Cardiology
      • Neurology
      • Others
  • Therapeutic Applications
    • Thyroid
    • Bone Metastasis
    • Lymphoma
    • Endocrine Tumors
    • Others

Nuclear Medicine Market, by Region

  • North America
    • U.S.
    • Canada
  • Europe
    • Germany
    • France
    • U.K.
    • Italy
    • Spain
    • Rest of Europe (RoE)
  • Asia-Pacific
  • Rest of the World (RoW)

Available Customizations

With the given market data, MarketsandMarkets offers customizations as per the company’s specific needs. The following customization option is available for the report:

Portfolio Assessment

Product Matrix, which gives a detailed comparison of the product portfolios of the top three companies in the market.

Table of Contents

1 Introduction (Page No. - 25)
    1.1 Objectives of Study
    1.2 Market Definition
           1.2.1 Markets Covered
           1.2.2 Years Considered for the Study
    1.3 Currency
    1.4 Limitations
    1.5 Stakeholders

2 Research Methodology (Page No. - 29)
    2.1 Research Methodology Steps
           2.1.1 Research Design
           2.1.2 Secondary and Primary Research Methodology
                    2.1.2.1 Secondary Research
                    2.1.2.2 Primary Research
                    2.1.2.3 Key Industry Insights
           2.1.3 Key Data From Primary Sources
           2.1.4 Key Insights From Primary Sources
           2.1.5 Market Size Estimation Methodology
           2.1.6 Market Data Validation and Triangulation
           2.1.7 Assumptions for the Study

3 Executive Summary (Page No. - 38)
    3.1 Introduction
    3.2 Conclusion

4 Premium Insights (Page No. - 41)
    4.1 Nuclear Medicine/ Radiopharmaceuticals: Market Overview
    4.2 Geographic Analysis: Nuclear Medicine Market, By PET Application (2016)
    4.3 Nuclear Medicine Market, By Type (2016 vs 2021)
    4.4 Geographical Snapshot of the Nuclear Medicine Market

5 Market Overview (Page No. - 44)
    5.1 Introduction
    5.2 Market Dynamics
           5.2.1 Drivers
                    5.2.1.1 Investment Through Public-Private Partnerships is Expected to Modernize Diagnostic Imaging Centers
                    5.2.1.2 Alpha Radioimmunotherapy (Rit)-Based Targeted Cancer Treatment
                    5.2.1.3 Advances in Radiotracers
                    5.2.1.4 Increasing Incidence and Prevalence of Cancer and Cardiac Ailments
           5.2.2 Restraints
                    5.2.2.1 Shorter Half-Life of Radiopharmaceuticals
                    5.2.2.2 High Cost of Nuclear Medicine Equipment
           5.2.3 Opportunities
                    5.2.3.1 High Demand in Emerging Markets
                    5.2.3.2 Upcoming Radioisotopes
                    5.2.3.3 Use of Radiopharmaceuticals in Neurological Applications
           5.2.4 Challenges
                    5.2.4.1 Shutdown of Nuclear Reactors

6 Nuclear Medicine/ Radiopharmaceuticals Market, By Type (Page No. - 51)
    6.1 Introduction
    6.2 Diagnostic Nuclear Medicine
           6.2.1 SPECT Radiopharmaceuticals
                    6.2.1.1 Tc-99m
                    6.2.1.2 Tl-201
                    6.2.1.3 Ga-67
                    6.2.1.4 I-123
                    6.2.1.5 Other SPECT Isotopes
           6.2.2 PET Radiopharmaceuticals
                    6.2.2.1 F-18
                    6.2.2.2 Rubidium-82
                    6.2.2.3 Other PET Isotopes
    6.3 Therapeutic Nuclear Medicine/ Radiopharmaceuticals
           6.3.1 Beta Emitters
                    6.3.1.1 Iodine-131
                    6.3.1.2 Y-90
                    6.3.1.3 Sm-153
                    6.3.1.4 Re-186
                    6.3.1.5 Lu-177
                    6.3.1.6 Other Beta Emitters
           6.3.2 Alpha Emitters
                    6.3.2.1 Ra-223
           6.3.3 Brachytherapy Isotopes
                    6.3.3.1 Iodine-125
                    6.3.3.2 Iridium-192
                    6.3.3.3 Palladium-103
                    6.3.3.4 Cesium-131
                    6.3.3.5 Other Brachytherapy Isotopes

7 Nuclear Medicine/ Radiopharmaceuticals Market, By Application (Page No. - 101)
    7.1 Introduction
    7.2 Diagnostic Applications
           7.2.1 SPECT Applications
                    7.2.1.1 Cardiology
                    7.2.1.2 Neurology
                    7.2.1.3 Thyroid
                    7.2.1.4 Other SPECT Applications
           7.2.2 PET Applications
                    7.2.2.1 Oncology
                    7.2.2.2 Cardiology
                    7.2.2.3 Neurology
                    7.2.2.4 Other PET Applications
    7.3 Therapeutic Applications
           7.3.1 Thyroid
           7.3.2 Bone Metastasis
           7.3.3 Lymphoma
           7.3.4 Endocrine Tumors
           7.3.5 Other Therapeutic Applications

8 Nuclear Medicine/ Radiopharmaceuticals Market, By Procedural Volume (Page No. - 132)
    8.1 Introduction
    8.2 Diagnostic Procedures
           8.2.1 SPECT Radiopharmaceuticals
           8.2.2 PET Radiopharmaceuticals
    8.3 Therapeutic Procedures
           8.3.1 Beta Emitters
           8.3.2 Alpha Emitters
           8.3.3 Brachytherapy Isotopes

9 Global Nuclear Medicine/ Radiopharmaceuticals Market, By Region (Page No. - 142)
    9.1 Introduction
    9.2 Diagnostics
           9.2.1 North America
           9.2.2 U.S.
                    9.2.2.1 Domestic Production of Mo-99 in the U.S.
                    9.2.2.2 Approval of New Radiopharmaceuticals By the FDA
           9.2.3 Canada
                    9.2.3.1 Extension of Operations at the Canadian Nru Reactor
                    9.2.3.2 Alternative Medical Isotope Technologies in Canada
    9.3 Europe
           9.3.1 Germany
                    9.3.1.1 New Irradiation Facility in Germany
           9.3.2 France
                    9.3.2.1 Shutdown of the French Osiris Nuclear Reactor
           9.3.3 U.K.
                    9.3.3.1 Increasing Adoption of Nuclear Medicine Equipment
           9.3.4 Italy
                    9.3.4.1 Steady Growth in Healthcare Expenditure
           9.3.5 Spain
                    9.3.5.1 Role of the Semnim in Spain
           9.3.6 Rest of Europe (RoE)
                    9.3.6.1 Rapid Rise in the Geriatric Population
    9.4 Asia-Pacific
           9.4.1 Installation of PET Scanners in India
           9.4.2 Investment By the Australian Government
           9.4.3 Initiatives to Promote Health
    9.5 RoW
           9.5.1 Iaea Initiatives in Latam
           9.5.2 Argentina’s Increasing Irradiation Capacity

10 Global Nuclear Medicine/ Radiopharmaceuticals Market, By Region (Page No. - 187)
     10.1 Therapeutic Nuclear Medicine Market
             10.1.1 North America
             10.1.2 U.S.
                        10.1.2.1 FDA Approval for Alpha Emitters
                        10.1.2.2 Therapeutic Nuclear Medicine Alternative Treatment Choice in Oncology
             10.1.3 Canada
                        10.1.3.1 Expertise in Isotope Production
                        10.1.3.2 Government Initiatives to Increase the Number of Nuclear Medicine Treatment Centers
             10.1.4 Europe
             10.1.5 Germany
                        10.1.5.1 Radionuklidtherapeutika A Research Program Conducted in Germany
             10.1.6 France
                        10.1.6.1 The Firm Project
             10.1.7 U.K.
                        10.1.7.1 ‘A Voice for Radiotherapy’ Initiative in the U.K.
             10.1.8 Italy
                        10.1.8.1 Growing Incidence of Cancer
             10.1.9 Spain
                        10.1.9.1 Rising Demand for Radiotherapeutics
             10.1.10 RoE
                        10.1.10.1 Government and Public–Private Investment
                        10.1.10.2 Research on Cancer in Poland
             10.1.11 Asia-Pacific
                        10.1.11.1 Increasing Aging Population in Japan
                        10.1.11.2 Aging Population and Increasing Cancer Prevalence in China
                        10.1.11.3 Approval of Ra-223 Dichloride By the Tga in Australia
             10.1.12 RoW
                        10.1.12.1 Increase in Cancer Incidence

11 Competitive Landscape (Page No. - 224)
     11.1 Overview
     11.2 Market Share Analysis
             11.2.1 Introduction
             11.2.2 Cardinal Health, Inc.
             11.2.3 Mallinckrodt PLC
             11.2.4 GE Healthcare
             11.2.5 Bayer Healthcare
             11.2.6 Lantheus Medical Imaging, Inc.
     11.3 Competitive Situations and Trends
             11.3.1 Agreements, Partnerships, and Contracts
             11.3.2 Marketing and Promotional Activities
             11.3.3 Expansions
             11.3.4 Acquisitions
             11.3.5 Product Approvals
             11.3.6 Divestments
             11.3.7 Product Launches
             11.3.8 Other Strategies

12 Company Profiles (Page No. - 237)
(Overview, Products and Services, Financials, Strategy & Development)*
     12.1 Introduction
     12.2 Cardinal Health, Inc.
     12.3 Mallinckrodt PLC 
     12.4 GE Healthcare (A Fully-Owned Subsidiary of General Electric Company)
     12.5 Lantheus Medical Imaging, Inc.
     12.6 Bayer AG
     12.7 Bracco Imaging S.P.A
     12.8 Eczacibasi-Monrol Nuclear Products
     12.9 Nordion, Inc. (A Subsidiary of Sterigenics International LLC.)
     12.10 Advanced Accelerator Applications S.A.
     12.11 Iba Molecular

*Details on Overview, Products and Services, Financials, Strategy & Development Might Not Be Captured in Case of Unlisted Companies.

13 Appendix (Page No. - 263)
     13.1 Insights of Industry Experts
     13.2 Discussion Guide
     13.3 Other Developments
             13.3.1 Cardinal Health, Inc.
             13.3.2 Mallinckrodt PLC
             13.3.3 GE Healthcare
             13.3.4 Lantheus Medical Imaging, Inc.
             13.3.5 Bayer AG
             13.3.6 Bracco Imaging S.P.A
             13.3.7 Eczacibasi-Monrol Nuclear Products
             13.3.8 Nordion, Inc.
             13.3.9 Advanced Accelerator Applications S.A.
             13.3.10 Iba Molecular
     13.4 Knowledge Store: Marketsandmarkets’ Subscription Portal
     13.5 Introducing RT: Real-Time Market Intelligence
     13.6 Available Customizations
     13.7 Related Reports
     13.8 Author Details


List of Tables (271 Tables)

Table 1 Nuclear Medicine/ Radiopharmaceuticals Market Size, By Type, 2014-2021 (USD Million)
Table 2 Diagnostic Nuclear Medicine/ Radiopharmaceuticals Market Size, By Type, 2014-2021 (USD Million)
Table 3 Diagnostic Nuclear Medicine/ Radiopharmaceuticals Market Size, By Region, 2014-2021 (USD Million)
Table 4 North America: Diagnostic Nuclear Medicine/ Radiopharmaceuticals Market Size, By Country, 2014-2021 (USD Million)
Table 5 Europe: Diagnostic Nuclear Medicine/ Radiopharmaceuticals Market Size, By Country, 2014-2021 (USD Million)
Table 6 SPECT Radiopharmaceuticals Market Size, By Type, 2014-2021 (USD Million)
Table 7 SPECT Radiopharmaceuticals Market Size, By Region, 2014-2021 (USD Million)
Table 8 North America: SPECT Radiopharmaceuticals Market Size, By Country, 2014-2021 (USD Million)
Table 9 Europe: SPECT Radiopharmaceuticals Market Size, By Country, 2014-2021 (USD Million)
Table 10 Tc-99m Market Size, By Region, 2014-2021 (USD Million)
Table 11 North America: Tc-99m Nuclear Medicine Market Size, By Country, 2014-2021 (USD Million)
Table 12 Europe: Tc-99m Market Size, By Country, 2014-2021 (USD Million)
Table 13 Tl-201 Market Size, By Region, 2014-2021 (USD Million)
Table 14 North America: Tl-201 Market Size, By Country, 2014-2021 (USD Million)
Table 15 Europe: Thallium-201 Market Size, By Country, 2014-2021 (USD Million)
Table 16 Ga-67 Market Size, By Region, 2014-2021 (USD Million)
Table 17 North America: Ga-67 Market Size, By Country, 2014-2021 (USD Million)
Table 18 Europe: Ga-67 Market Size, By Country, 2014-2021 (USD Million)
Table 19 I-123 Market Size, By Region, 2014-2021 (USD Million)
Table 20 North America: I-123 Market Size, By Country, 2014-2021 (USD Million)
Table 21 Europe: I-123 Market Size, By Country, 2014-2021 (USD Million)
Table 22 Other SPECT Isotopes Market Size, By Region, 2014-2021 (USD Million)
Table 23 North America: Other SPECT Isotopes Market Size, By Country, 2014-2021 (USD Million)
Table 24 Europe: Other SPECT Isotopes Market Size, By Country, 2014-2021 (USD Million)
Table 25 PET Radiopharmaceuticals Market Size, By Type, 2014-2021 (USD Million)
Table 26 PET Radiopharmaceuticals Market Size, By Region, 2014-2021 (USD Million)
Table 27 North America: PET Radiopharmaceuticals Market Size, By Country, 2014-2021 (USD Million)
Table 28 Europe: PET Radiopharmaceuticals Market Size, By Country, 2014-2021 (USD Million)
Table 29 F-18 Market Size, By Region, 2014-2021 (USD Million)
Table 30 North America: F-18 Market Size, By Country, 2014-2021 (USD Million)
Table 31 Europe: F-18 Market Size, By Country, 2014-2021 (USD Million)
Table 32 Rubidium-82 Market Size, By Region, 2014-2021 (USD Million)
Table 33 North America: Rubidium-82 Market Size, By Country, 2014-2021 (USD Million)
Table 34 Europe: Rubidium-82 Market Size, By Country, 2014-2021 (USD Million)
Table 35 Other PET Isotopes Market Size, By Region, 2014-2021 (USD Million)
Table 36 North America: Other PET Isotopes Nuclear Market Size, By Country, 2014-2021 (USD Million)
Table 37 Europe: Other PET Isotopes Market Size, By Country, 2014-2021 (USD Million)
Table 38 Therapeutic Nuclear Medicine Market Size, By Type, 2014–2021 (USD Million)
Table 39 Therapeutic Nuclear Medicine/ Radiopharmaceuticals Market Size, By Region, 2014–2021 (USD Million)
Table 40 North America: Therapeutic Nuclear Medicine/ Radiopharmaceuticals Market Size, By Country, 2014–2021 (USD Million)
Table 41 Europe: Therapeutic Nuclear Medicine Market Size, By Country, 2014–2021 (USD Million)
Table 42 Beta Emitters Market Size, By Type, 2014–2021 (USD Million)
Table 43 Beta Emitters Market Size, By Region, 2014–2021 (USD Million)
Table 44 North America: Beta Emitters Market Size, By Country, 2014–2021 (USD Million)
Table 45 Europe: Beta Emitters Market Size, By Country, 2014–2021 (USD Million)
Table 46 Iodine-131 Market Size, By Region, 2014–2021 (USD Million)
Table 47 North America: Iodine-131 Market Size, By Country, 2014–2021 (USD Million)
Table 48 Europe: I-131 Market Size, By Country, 2014–2021 (USD Million)
Table 49 Y-90 Market Size, By Region, 2014–2021 (USD Million)
Table 50 North America: Y-90 Market Size, By Country, 2014–2021 (USD Million)
Table 51 Europe: Y-90 Market Size, By Country, 2014–2021 (USD Million)
Table 52 Sm-153 Market Size, By Region, 2014–2021 (USD Million)
Table 53 North America: Sm-153 Market Size, By Country, 2014–2021 (USD Million)
Table 54 Europe: Sm-153 Market Size, By Country, 2014–2021 (USD Million)
Table 55 Re-186 Market Size, By Region, 2014–2021 (USD Million)
Table 56 North America: Re-186 Market Size, By Country, 2014–2021 (USD Million)
Table 57 Europe: Re-186 Market Size, By Country, 2014–2021 (USD Million)
Table 58 Lu-177 Market Size, By Region, 2014–2021 (USD Million)
Table 59 North America: Lu-177 Market Size, By Country, 2014–2021 (USD Million)
Table 60 Europe: Lu-177 Market Size, By Country, 2014–2021 (USD Million)
Table 61 Other Beta Emitters Market Size, By Region, 2014–2021 (USD Million)
Table 62 North America: Other Beta Emitters Market Size, By Country, 2014–2021 (USD Million)
Table 63 Europe: Other Beta Emitters Market Size, By Country, 2014–2021 (USD Million)
Table 64 Ra-223 Market Size, By Region, 2014–2021 (USD Million)
Table 65 North America: Ra-223 Market Size, By Country, 2014–2021 (USD Million)
Table 66 Europe: Radium-223 Market Size, By Country, 2014–2021 (USD Million)
Table 67 Brachytherapy Isotopes Market Size, By Type, 2014–2021 (USD Million)
Table 68 Brachytherapy Isotopes Market Size, By Region, 2014–2021 (USD Million)
Table 69 North America: Brachytherapy Isotopes Market Size, By Country, 2014–2021 (USD Million)
Table 70 Europe: Brachytherapy Isotopes Market Size, By Country, 2014–2021 (USD Million)
Table 71 I-125 Market Size, By Region, 2014–2021 (USD Million)
Table 72 North America: Iodine-125 Market Size, By Country, 2014–2021 (USD Million)
Table 73 Europe: Iodine-125 Market Size, By Country, 2014–2021 (USD Million)
Table 74 Iridium-192 Market Size, By Region, 2014–2021 (USD Million)
Table 75 North America: Iridium-192 Market Size, By Country, 2014–2021 (USD Million)
Table 76 Europe: Iridium-192 Market Size, By Country, 2014–2021 (USD Million)
Table 77 Palladium-103 Market Size, By Region, 2014–2021 (USD Million)
Table 78 North America: Palladium-103 Market Size, By Country, 2014–2021 (USD Million)
Table 79 Europe: Pd-103 Market Size, By Country, 2014–2021 (USD Million)
Table 80 Cesium-131 Market Size, By Region, 2014–2021 (USD Million)
Table 81 North America: Cesium-131 Market Size, By Country, 2014–2021 (USD Million)
Table 82 Europe: Cesium-131 Market Size, By Country, 2014–2021 (USD Million)
Table 83 Other Brachytherapy Isotopes Market Size, By Region, 2014–2021 (USD Million)
Table 84 North America: Other Brachytherapy Isotopes Market Size, By Country, 2014–2021 (USD Million)
Table 85 Europe: Other Brachytherapy Isotopes Market Size, By Country, 2014–2021 (USD Million)
Table 86 SPECT Applications Market Size, By Type, 2014-2021 (USD Million)
Table 87 SPECT Applications Market Size, By Region, 2014–2021 (USD Million)
Table 88 North America: SPECT Applications Market Size, By Country, 2014–2021 (USD Million)
Table 89 Europe: SPECT Applications Market Size, By Country, 2014–2021 (USD Million)
Table 90 Cardiology Applications Market Size, By Region, 2014-2021 (USD Million)
Table 91 North America: Cardiology Applications Market Size, By Country, 2014-2021 (USD Million)
Table 92 Europe: Cardiology Applications Market Size, By Country, 2014-2021 (USD Million)
Table 93 Neurology Applications Market Size, By Region, 2014-2021 (USD Million)
Table 94 North America: Neurology Applications Market Size, By Country, 2014-2021 (USD Million)
Table 95 Europe: Neurology Applications Market Size, By Country, 2014-2021 (USD Million)
Table 96 Thyroid Applications Market Size, By Region, 2014-2021 (USD Million)
Table 97 North America: Thyroid Applications Market Size, By Country, 2014-2021 (USD Million)
Table 98 Europe: Thyroid Applications Market Size, By Country, 2014-2021 (USD Million)
Table 99 Other SPECT Applications Market Size, By Region, 2014-2021 (USD Million)
Table 100 North America: Other SPECT Applications Market Size, By Country, 2014-2021 (USD Million)
Table 101 Europe: Other SPECT Applications Market Size, By Country, 2014-2021 (USD Million)
Table 102 PET Applications Market Size, By Type, 2014-2021 (USD Million)
Table 103 PET Applications Market Size, By Region, 2014–2021 (USD Million)
Table 104 North America: PET Applications Market Size, By Country, 2014–2021 (USD Million)
Table 105 Europe: PET Applications Market Size, By Country, 2014–2021 (USD Million)
Table 106 Oncology Applications Market Size, By Region, 2014-2021 (USD Million)
Table 107 North America: Oncology Applications Market Size, By Country, 2014-2021 (USD Million)
Table 108 Europe: Oncology Applications Market Size, By Country, 2014-2021 (USD Million)
Table 109 Cardiology Applications Market Size, By Region, 2014-2021 (USD Million)
Table 110 North America: Cardiology Applications Market Size, By Country, 2014-2021 (USD Million)
Table 111 Europe: Cardiology Applications Market Size, By Country, 2014-2021 (USD Million)
Table 112 Neurology Applications Market Size, By Region, 2014-2021 (USD Million)
Table 113 North America: Neurology Applications Market Size, By Country, 2014-2021 (USD Million)
Table 114 Europe: Neurology Applications Market Size, By Country, 2014-2021 (USD Million)
Table 115 Other PET Applications Market Size, By Region, 2014-2021 (USD Million)
Table 116 North America: Other PET Applications Market Size, By Country, 2014-2021 (USD Million)
Table 117 Europe: Other PET Applications Market Size, By Country, 2014-2021 (USD Million)
Table 118 Therapeutic Applications Market Size, By Type, 2014-2021 (USD Million)
Table 119 Thyroid Applications Market Size, By Region, 2014-2021 (USD Million)
Table 120 North America: Thyroid Applications Market Size, By Country, 2014-2021 (USD Million)
Table 121 Europe: Thyroid Applications Market Size, By Country, 2014-2021 (USD Million)
Table 122 Bone Metastasis Applications Market Size, By Region, 2014-2021 (USD Million)
Table 123 North America: Bone Metastasis Applications Market Size, By Country, 2014-2021 (USD Million)
Table 124 Europe: Bone Metastasis Applications Market Size, By Country, 2014-2021 (USD Million)
Table 125 Lymphoma Applications Market Size, By Region, 2014-2021 (USD Million)
Table 126 North America: Lymphoma Applications Market Size, By Country, 2014-2021 (USD Million)
Table 127 Europe: Lymphoma Applications Market Size, By Country, 2014-2021 (USD Million)
Table 128 Endocrine Tumor Applications Market Size, By Region, 2014-2021 (USD Million)
Table 129 North America: Endocrine Tumor Applications Market Size, By Country, 2014-2021 (USD Million)
Table 130 Europe: Endocrine Tumor Applications Market Size, By Country, 2014-2021 (USD Million)
Table 131 Other Therapeutic Applications Market Size, By Region, 2014-2021 (USD Million)
Table 132 North America: Other Therapeutic Applications Market Size, By Country, 2014-2021 (USD Million)
Table 133 Europe: Other Therapeutic Applications Market Size, By Country, 2014-2021 (USD Million)
Table 134 Nuclear Medicine Market, By Procedural Volume, 2014–2021 (Thousand Units)
Table 135 Nuclear Medicine/ Radiopharmaceuticals Market Size, By Region, 2014–2021 (Thousand Units)
Table 136 Diagnostic Nuclear Medicine Market Size, By Type, 2014–2021 (Thousand Units)
Table 137 Diagnostic Nuclear Medicine Market Size, By Region, 2014–2021 (Thousand Units)
Table 138 SPECT Nuclear Medicine/ Radiopharmaceuticals Market Size, By Type, 2014–2021 (Thousand Units)
Table 139 SPECT Nuclear Medicine Market Size, By Region, 2014–2021 (Thousand Units)
Table 140 PET Nuclear Medicine Market Size, By Type, 2014–2021 (Thousand Units)
Table 141 PET Nuclear Medicine/ Radiopharmaceuticals Market Size, By Type, 2014–2021 (Thousand Units)
Table 142 Therapeutic Nuclear Medicine Market Size, By Type, 2014–2021 (Thousand Units)
Table 143 Therapeutic Nuclear Medicine Market Size, By Region, 2014–2021 (Thousand Units)
Table 144 Beta Emitter Nuclear Medicine Market Size, By Type, 2014–2021 (Thousand Units)
Table 145 Beta Emitter Nuclear Medicine/ Radiopharmaceuticals Market Size, By Region, 2014–2021 (Thousand Units)
Table 146 Alpha Emitter Nuclear Medicine/ Radiopharmaceuticals Market Size, By Region, 2014–2021 (Thousand Units)
Table 147 Brachytherapy Isotopes Nuclear Medicine Market Size, By Type, 2014–2021 (Thousand Units)
Table 148 Brachytherapy Isotopes Nuclear Medicine/ Radiopharmaceuticals Market Size, By Region, 2014–2021 (Thousand Units)
Table 149 Global Nuclear Medicine/ Radiopharmaceuticals Market Size, By Region, 2014–2021 (USD Million)
Table 150 Diagnostic Nuclear Medicine Market Size, By Region, 2014–2021 (USD Million)
Table 151 North America: Diagnostic Radiopharmaceuticals Market Size, By Country, 2014–2021 (USD Million)
Table 152 North America: Diagnostic Nuclear Medicine/ Radiopharmaceuticals Market Size, By Type, 2014–2021 (USD Million)
Table 153 North America: SPECT Nuclear Medicine Market Size, By Type, 2014–2021 (USD Million)
Table 154 North America: SPECT Nuclear Medicine/ Radiopharmaceuticals Market Size, By Application, 2014–2021 (USD Million)
Table 155 North America: PET Nuclear Medicine/Radiopharmaceuticals Market Size, By Type, 2014–2021 (USD Million)
Table 156 North America: PET Nuclear Medicine Market Size, By Application, 2014–2021 (USD Million)
Table 157 U.S.: Diagnostic Nuclear Medicine/ Radiopharmaceuticals Market Size, By Type, 2014–2021 (USD Million)
Table 158 U.S.: SPECT Nuclear Medicine/ Radiopharmaceuticals Market Size, By Type, 2014–2021 (USD Million)
Table 159 U.S.: SPECT Nuclear Medicine/ Radiopharmaceuticals Market Size, By Application, 2014–2021 (USD Million)
Table 160 U.S.: PET Nuclear Medicine Market Size, By Type, 2014–2021 (USD Million)
Table 161 U.S.: PET Nuclear Medicine/ Radiopharmaceuticals Market Size, By Application, 2014–2021 (USD Million)
Table 162 Canada: Diagnostic Nuclear Medicine/ Radiopharmaceuticals Market Size, By Type, 2014–2021 (USD Million)
Table 163 Canada: SPECT Nuclear Medicine Market Size, By Type, 2014–2021 (USD Million)
Table 164 Canada: SPECT Nuclear Medicine/ Radiopharmaceuticals Market Size, By Application, 2014–2021 (USD Million)
Table 165 Canada: PET Nuclear Medicine/ Radiopharmaceuticals Market Size, By Type, 2014–2021 (USD Million)
Table 166 Canada: PET Nuclear Medicine/Radiopharmaceuticals Market Size, By Application, 2014–2021 (USD Million)
Table 167 Europe: Diagnostic Nuclear Medicine/ Radiopharmaceuticals Market Size, By Country, 2014–2021 (USD Million)
Table 168 Europe: Diagnostic Nuclear Medicine/ Radiopharmaceuticals Market Size, By Type, 2014–2021 (USD Million)
Table 169 Europe: SPECT Nuclear Medicine/ Radiopharmaceuticals Market Size, By Type, 2014–2021 (USD Million)
Table 170 Europe: SPECT Nuclear Medicine Market Size, By Application, 2014–2021 (USD Million)
Table 171 Europe: PET Nuclear Medicine/ Radiopharmaceuticals Market Size, By Type, 2014–2021 (USD Million)
Table 172 Europe: PET Nuclear Medicine/ Radiopharmaceuticals Market Size, By Application, 2014–2021 (USD Million)
Table 173 Germany: Diagnostic Radiopharmaceuticals Market Size, By Type, 2014–2021 (USD Million)
Table 174 Germany: SPECT Nuclear Medicine/ Radiopharmaceuticals Market Size, By Type, 2014–2021 (USD Million)
Table 175 Germany: SPECT Nuclear Medicine/ Radiopharmaceuticals Market Size, By Application, 2014–2021 (USD Million)
Table 176 Germany: PET Nuclear Medicine/ Radiopharmaceuticals Market Size, By Type, 2014–2021 (USD Million)
Table 177 Germany: PET Radiopharmaceuticals Market Size, By Application, 2014–2021 (USD Million)
Table 178 France: Diagnostic Nuclear Medicine/ Radiopharmaceuticals Market Size, By Type, 2014–2021 (USD Million)
Table 179 France: SPECT Nuclear Medicine/ Radiopharmaceuticals Market Size, By Type, 2014–2021 (USD Million)
Table 180 France: SPECT Nuclear Medicine/ Radiopharmaceuticals Market Size, By Application, 2014–2021 (USD Million)
Table 181 France: PET Nuclear Medicine/ Radiopharmaceuticals Market Size, By Type, 2014–2021 (USD Million)
Table 182 France: PET Nuclear Medicine/ Radiopharmaceuticals Market Size, By Application, 2014–2021 (USD Million)
Table 183 U.K.: Diagnostic Nuclear Medicine/ Radiopharmaceuticals Market Size, By Type, 2014–2021 (USD Million)
Table 184 U.K.: SPECT Nuclear Medicine/ Radiopharmaceuticals Market Size, By Type, 2014–2021 (USD Million)
Table 185 U.K.: SPECT Nuclear Medicine/ Radiopharmaceuticals Market Size, By Application, 2014–2021 (USD Million)
Table 186 U.K.: PET Nuclear Medicine/ Radiopharmaceuticals Market Size, By Type, 2014–2021 (USD Million)
Table 187 U.K.: PET Nuclear Medicine/ Radiopharmaceuticals Market Size, By Application, 2014–2021 (USD Million)
Table 188 Italy: Diagnostic Nuclear Medicine/ Radiopharmaceuticals Market Size, By Type, 2014–2021 (USD Million)
Table 189 Italy: SPECT Nuclear Medicine/ Radiopharmaceuticals Market Size, By Type, 2014–2021 (USD Million)
Table 190 Italy: SPECT Nuclear Medicine/ Radiopharmaceuticals Market Size, By Application, 2014–2021 (USD Million)
Table 191 Italy: PET Nuclear Medicine/ Radiopharmaceuticals Market Size, By Type, 2014–2021 (USD Million)
Table 192 Italy: PET Nuclear Medicine/ Radiopharmaceuticals Market Size, By Application, 2014–2021 (USD Million)
Table 193 Spain: Diagnostic Nuclear Medicine/ Radiopharmaceuticals Market Size, By Type, 2014–2021 (USD Million)
Table 194 Spain: SPECT Nuclear Medicine/ Radiopharmaceuticals Market Size, By Type, 2014–2021 (USD Million)
Table 195 Spain: SPECT Nuclear Medicine/ Radiopharmaceuticals Market Size, By Application, 2014–2021 (USD Million)
Table 196 Spain: PET Radiopharmaceuticals Market Size, By Type, 2014–2021 (USD Million)
Table 197 Spain: PET Nuclear Medicine/ Radiopharmaceuticals Market Size, By Application, 2014–2021 (USD Million)
Table 198 RoE: Diagnostic Nuclear Medicine/ Radiopharmaceuticals Market Size, By Type, 2014–2021 (USD Million)
Table 199 RoE: SPECT Nuclear Medicine/ Radiopharmaceuticals Market Size, By Type, 2014–2021 (USD Million)
Table 200 RoE: SPECT Nuclear Medicine/ Radiopharmaceuticals Market Size, By Application, 2014–2021 (USD Million)
Table 201 RoE: PET Radiopharmaceuticals Market Size, By Type, 2014–2021 (USD Million)
Table 202 RoE: PET Nuclear Medicine/ Radiopharmaceuticals Market Size, By Application, 2014–2021 (USD Million)
Table 203 Asia-Pacific: Diagnostic Nuclear Medicine/ Radiopharmaceuticals Market Size, By Type, 2014–2021 (USD Million)
Table 204 Asia-Pacific: SPECT Nuclear Medicine/ Radiopharmaceuticals Market Size, By Type, 2014–2021 (USD Million)
Table 205 Asia-Pacific: SPECT Radiopharmaceuticals Market Size, By Application, 2014–2021 (USD Million)
Table 206 Asia-Pacific: PET Radiopharmaceuticals Market Size, By Type, 2014–2021 (USD Million)
Table 207 Asia-Pacific: PET Nuclear Medicine/ Radiopharmaceuticals Market Size, By Application, 2014–2021 (USD Million)
Table 208 RoW: Diagnostic Radiopharmaceuticals Market Size, By Type, 2014–2021 (USD Million)
Table 209 RoW: SPECT Radiopharmaceuticals Market Size, By Type, 2014–2021 (USD Million)
Table 210 RoW: SPECT Nuclear Medicine/ Radiopharmaceuticals Market Size, By Application, 2014–2021 (USD Million)
Table 211 RoW: PET Nuclear Medicine/ Radiopharmaceuticals Market Size, By Type, 2014–2021 (USD Million)
Table 212 RoW: PET Radiopharmaceuticals Market Size, By Application, 2014–2021 (USD Million)
Table 213 Therapeutic Radiopharmaceuticals Market Size, By Region, 2014–2021 (USD Million)
Table 214 North America: Therapeutic Radiopharmaceuticals Market Size, By Country, 2014–2021 (USD Million)
Table 215 North America: Therapeutic Nuclear Medicine/ Radiopharmaceuticals Market Size, By Type, 2014–2021 (USD Million)
Table 216 North America: Beta Emitters Market Size, By Type, 2014–2021 (USD Million)
Table 217 North America: Brachytherapy Isotopes Market Size, By Type, 2014–2021 (USD Million)
Table 218 North America: Therapeutic Nuclear Medicine/ Radiopharmaceuticals Market Size, By Application, 2014–2021 (USD Million)
Table 219 U.S.: Therapeutic Nuclear Medicine/ Radiopharmaceuticals Market Size, By Type, 2014–2021 (USD Million)
Table 220 U.S.: Beta Emitters Market Size, By Type, 2014–2021 (USD Million)
Table 221 U.S.: Brachytherapy Isotopes Market Size, By Type, 2014–2021 (USD Million)
Table 222 U.S.: Therapeutic Nuclear Medicine/ Radiopharmaceuticals Market Size, By Application, 2014–2021 (USD Million)
Table 223 Canada: Therapeutic Nuclear Medicine/ Radiopharmaceuticals Market Size, By Type, 2014–2021 (USD Million)
Table 224 Canada: Beta Emitters Market Size, By Type, 2014–2021 (USD Million)
Table 225 Canada: Brachytherapy Isotopes Market Size, By Type, 2014–2021 (USD Million)
Table 226 Canada: Therapeutic Nuclear Medicine/ Radiopharmaceuticals Market Size, By Application, 2014–2021 (USD Million)
Table 227 Europe: Therapeutic Radiopharmaceuticals Market Size, By Country, 2014–2021 (USD Million)
Table 228 Europe: Therapeutic Radiopharmaceuticals Market Size, By Type, 2014–2021 (USD Million)
Table 229 Europe: Beta Emitters Market Size, By Type, 2014–2021 (USD Million)
Table 230 Europe: Brachytherapy Isotopes Market Size, By Type, 2014–2021 (USD Million)
Table 231 Europe: Therapeutic Nuclear Medicine/ Radiopharmaceuticals Market Size, By Application, 2014–2021 (USD Million)
Table 232 Germany: Therapeutic Nuclear Medicine/ Radiopharmaceuticals Market Size, By Type, 2014–2021 (USD Million)
Table 233 Germany: Beta Emitters Market Size, By Type, 2014–2021 (USD Million)
Table 234 Germany: Brachytherapy Isotopes Market Size, By Type, 2014–2021 (USD Million)
Table 235 Germany: Therapeutic Nuclear Medicine/ Radiopharmaceuticals Market Size, By Application, 2014–2021 (USD Million)
Table 236 France: Therapeutic Nuclear Medicine/ Radiopharmaceuticals Market Size, By Type, 2014–2021 (USD Million)
Table 237 France: Beta Emitters Market Size, By Type, 2014–2021 (USD Million)
Table 238 France: Brachytherapy Isotopes Market Size, By Type, 2014–2021 (USD Million)
Table 239 France: Therapeutic Nuclear Medicine/ Radiopharmaceuticals Market Size, By Application, 2014–2021 (USD Million)
Table 240 U.K.: Therapeutic Nuclear Medicine/ Radiopharmaceuticals Market Size, By Type, 2014–2021 (USD Million)
Table 241 U.K.: Beta Emitters Market Size, By Type, 2014–2021 (USD Million)
Table 242 U.K.: Brachytherapy Isotopes Market Size, By Type, 2014–2021 (USD Million)
Table 243 U.K.: Therapeutic Nuclear Medicine/ Radiopharmaceuticals Market Size, By Application, 2014–2021 (USD Million)
Table 244 Italy: Therapeutic Nuclear Medicine/ Radiopharmaceuticals Market Size, By Type, 2014–2021 (USD Million)
Table 245 Italy: Beta Emitters Market Size, By Type, 2014–2021 (USD Million)
Table 246 Italy: Brachytherapy Isotopes Market Size, By Type, 2014–2021 (USD Million)
Table 247 Italy: Therapeutic Nuclear Medicine/ Radiopharmaceuticals Market Size, By Application, 2014–2021 (USD Million)
Table 248 Spain: Therapeutic Nuclear Medicine/ Radiopharmaceuticals Market Size, By Type, 2014–2021 (USD Million)
Table 249 Spain: Beta Emitters Market Size, By Type, 2014–2021 (USD Million)
Table 250 Spain: Brachytherapy Isotopes Market Size, By Type, 2014–2021 (USD Million)
Table 251 Spain: Therapeutic Nuclear Medicine/ Radiopharmaceuticals Market Size, By Application, 2014–2021 (USD Million)
Table 252 RoE: Therapeutic Nuclear Medicine/ Radiopharmaceuticals Market Size, By Type, 2014–2021 (USD Million)
Table 253 RoE: Beta Emitters Market Size, By Type, 2014–2021 (USD Million)
Table 254 RoE: Brachytherapy Isotopes Market Size, By Type, 2014–2021 (USD Million)
Table 255 RoE: Therapeutic Nuclear Medicine/ Radiopharmaceuticals Market Size, By Application, 2014–2021 (USD Million)
Table 256 Asia-Pacific: Therapeutic Nuclear Medicine Market Size, By Type, 2014–2021 (USD Million)
Table 257 Asia-Pacific: Beta Emitters Market Size, By Type, 2014–2021 (USD Million)
Table 258 Asia-Pacific: Brachytherapy Isotopes Market Size, By Type, 2014–2021 (USD Million)
Table 259 Asia-Pacific: Therapeutic Nuclear Medicine/ Radiopharmaceuticals Market Size, By Application, 2014–2021 (USD Million)
Table 260 RoW: Therapeutic Nuclear Medicine/ Radiopharmaceuticals Market Size, By Type, 2014–2021 (USD Million)
Table 261 RoW: Beta Emitters Market Size, By Type, 2014–2021 (USD Million)
Table 262 RoW: Brachytherapy Isotopes Market Size, By Type, 2014–2021 (USD Million)
Table 263 RoW: Therapeutic Nuclear Medicine/ Radiopharmaceuticals Market Size, By Application, 2014–2021 (USD Million)
Table 264 Agreements, Partnerships, and Contracts (2013–2016)
Table 265 Marketing and Promotional Activities (2013–2016)
Table 266 Expansions (2013–2016)
Table 267 Acquisitions (2013–2016)
Table 268 Product Approvals (2013–2016)
Table 269 Divestments (2013–2016)
Table 270 Product Launches (2013–2016)
Table 271 Other Strategies (2013–2016)
 
 
List of Figures (49 Figures)
 
Figure 1 Global Nuclear Medicine/ Radiopharmaceuticals Market Segmentation
Figure 2 Global Nuclear Medicine/ Radiopharmaceuticals Market: Research Methodology Steps
Figure 3 Break Down of Primary Interviews: By Company Type, Designation, and Region
Figure 4 Market Size Estimation Methodology: Bottom-Up Approach
Figure 5 Market Size Estimation Methodology: Top-Down Approach
Figure 6 Data Triangulation Methodology
Figure 7 Global Nuclear Medicine/ Radiopharmaceuticals Market Analysis, By Type (2016 vs 2021)
Figure 8 Global Nuclear Medicine/ Radiopharmaceuticals Diagnostic Applications Market Size, By SPECT Technique, 2016 vs 2021 (USD Million)
Figure 9 Asia-Pacific to Witness the Highest CAGR During the Forecast Period
Figure 10 Nuclear Medicine/ Radiopharmaceuticals Market is Projected to Witness A High CAGR in the Forecast Period
Figure 11 Oncology Segment is Expected to Dominate the PET Applications Market in 2016
Figure 12 Diagnostics Segment is Expected to Continue to Dominate the Radiopharmaceuticals Market Until 2021
Figure 13 APAC is Expected to Witness the Highest CAGR During the Forecast Period
Figure 14 Nuclear Medicine Market: Drivers, Restraints, Opportunities, & Challenges
Figure 15 Diagnostics Segment is Expected to Command the Largest Share of the Nuclear Medicine Market in 2016
Figure 16 PET Segment to Grow at the Higher CAGR During the Forecast Period
Figure 17 Alpha Emitters Segment is Expected to Register the Highest CAGR During the Forecast Period
Figure 18 Neurology Applications Segment is Expected to Grow at the Highest CAGR During the Forecast Period
Figure 19 Neurology Applications Segment is Expected to Grow at the Highest CAGR During the Forecast Period
Figure 20 Endocrine Tumors Application Segment is Expected to Grow at the Highest CAGR During the Forecast Period
Figure 21 Nuclear Medicine Market, By Procedural Volume (2016 vs 2021)
Figure 22 North America is Expected to Dominate the Diagnostic Nuclear Medicine Market in 2016
Figure 23 North America: Diagnostic Nuclear Medicine/Radiopharmaceuticals Market Snapshot
Figure 24 Europe: Diagnostic Nuclear Medicine/ Radiopharmaceuticals Market Snapshot
Figure 25 Asia-Pacific: Diagnostic Nuclear Medicine/ Radiopharmaceuticals Market Snapshot
Figure 26 RoW Diagnostic Nuclear Medicine/ Radiopharmaceuticals Market Snapshot
Figure 27 North America is Expected to Dominate the Therapeutic Nuclear Medicine Market in 2016
Figure 28 North America: Therapeutic Nuclear Medicine Market Snapshot
Figure 29 Europe: Therapeutic Nuclear Medicine Market Snapshot
Figure 30 Asia-Pacific Therapeutic Nuclear Medicine Market Snapshot
Figure 31 RoW Therapeutic Nuclear Medicine/ Radiopharmaceuticals Market Snapshot
Figure 32 Agreements, Partnerships, and Contracts Were the Key Growth Strategy Adopted By Market Companies Between 2013 and 2016
Figure 33 Nuclear Medicine Market Share, By Key Company (2015)
Figure 34 Agreements, Partnerships, and Contracts are the Key Growth Strategy Adopted By Market Companies
Figure 35 Agreements, Partnerships, and Contracts, By Company (2013–2016)
Figure 36 Marketing and Promotional Activities, By Company (2013–2016)
Figure 37 Expansions, By Company (2013–2016)
Figure 38 Acquisitions, By Company (2013–2016)
Figure 39 Product Approvals, By Company (2013–2016)
Figure 40 Divestments, By Company (2013–2016)
Figure 41 Product Launches, By Company (2013–2016)
Figure 42 Other Strategies, By Company (2013–2016)
Figure 43 Geographic Revenue Mix of Prominent Companies (2015)
Figure 44 Cardinal Health, Inc.: Company Snapshot
Figure 45 Mallinckrodt PLC: Company Snapshot
Figure 46 GE Healthcare: Company Snapshot
Figure 47 Lantheus Medical Imaging, Inc.: Company Snapshot
Figure 48 Bayer AG: Company Snapshot
Figure 49 Advanced Accelerator Applications S.A.: Company Snapshot

The nuclear medicine market is projected to reach USD 7.27 Billion by 2021 from USD 4.67 Billion in 2016, growing at a CAGR of 9.3% during the forecast period, owing to factors such as the introduction of alpha emitters for targeted cancer therapy, increasing prevalence of cancer and cardiovascular diseases, increasing geriatric population in China and India, initiatives by government bodies are expected to drive the growth of the market.

The global market is segmented on the basis of type, application, procedural volume, and region. Based on type, the market is segmented into diagnostic and therapeutic. The diagnostic segment accounted for the largest share of the nuclear medicine market. The diagnostic segment is further segmented into SPECT and PET. In 2016, the SPECT segment accounted for the largest share of the radiopharmaceuticals diagnostic market. The therapeutic segment is further segmented into beta emitters, alpha emitters, and brachytherapy. In 2016, the beta emitters segment accounted for the largest share of the nuclear medicine/radiopharmaceuticals therapeutic market.

Based on application, the nuclear medicine market is segmented into diagnostic applications for SPECT & PET and therapeutic applications. In 2016, the SPECT applications segment accounted for the largest share of the market. The large share of this application segment can primarily be attributed to factors such as the mature SPECT imaging market and the extensive usage of SPECT radioisotopes for the diagnosis of various diseases, including cancer, cardiovascular diseases, thyroid, and neurological disorders.

Based on region, the nuclear medicine market is segmented into North America, Europe, Asia-Pacific, and the Rest of the World. In 2016, North America is estimated to account for the largest share, followed by Asia-Pacific and Europe. The Asia-Pacific region is expected to grow at the highest CAGR during the forecast period. This high growth can be attributed to the installation of PET scanners in India and initiatives by the government of the Asian countries to promote health among others.

Nuclear Medicine/Radiopharmaceuticals Market

The major players in the global nuclear medicine market include Cardinal Health Inc. (U.S.), GE Healthcare (U.K.), Bracco Imaging S.p.A (Italy), Eczacibasi-Monrol Nuclear Products (Turkey), Nordion, Inc. (Canada), Advanced Accelerator Applications S.A. (France), Bayer Healthcare (Germany), Lantheus Medical Imaging, Inc. (U.S.), IBA Molecular Imaging (Belgium), and Mallinckrodt plc (Ireland).

To speak to our analyst for a discussion on the above findings, click Speak to Analyst

Custom Market Research Services

We will customize the research for you, in case the report listed above does not meet with your exact requirements. Our custom research will comprehensively cover the business information you require to help you arrive at strategic and profitable business decisions.

Please visit https://www.marketsandmarkets.com/knowledge-process-outsourcing-services.asp to specify your custom Research Requirement

Connect With Us

Follow us on LinkedIn  Follow us on Facebook   Follow us on Twitter 
Live Chat Support


US : 1-888-600-6441
UK : 44-800-368-9399

Search reports



Access reports on all high
growth Pharmaceuticals Markets on KnowledgeStore
Request Demo